Lundbeck and Solvay have announced that they are discontinuing development of bifeprunox for the maintenance treatment of schizophrenia.
Lundbeck and Solvay have announced that they are discontinuing development of bifeprunox for the maintenance treatment of schizophrenia.
After analyzing results from an interim analysis of pooled data, the companies decided that the efficacy data did not support continued development of this agent for the stabilization of nonacute schizophrenia.
FDA issued a nonapprovable letter for bifeprunox for the acute and maintenance treatment of schizophrenia in August 2007. In its letter, FDA stated that a second study would be needed to support the approval of bifeprunox for the maintenance treatment of schizophrenia. The agency also stated that the efficacy data were not sufficient for the approval of bifeprunox for the acute treatment of schizophrenia.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More